Johnson & Johnson, which in-licensed Legend's CAR-T technology and is developing a version of its product under the name JNJ-4528, presented data from the Phase Ib/II CARTITUDE-1 study at the ASCO meeting.
Data for the drug, CC-92480, showed an overall response rate of more than 54% when given at the recommended Phase II dose in 11 heavily pretreated patients. The drug is part of a new class known as CELMoD agents.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Data on multiple CAR-Ts presented at the recent ASCO meeting have raised the prospect of outpatient use of the therapies, which is favorable for reimbursement as well as for patients. But experts pointed to significant infrastructure challenges that centers face.
An investigator in the Phase I/II trial of Amgen's AMG 510 said that while data for colorectal cancer indicated low activity as a single agent, it nevertheless represented a doubling in progression-free survival over what is seen from currently available treatments.
In a presentation of data at ASCO on the Phase I/II study of orvacabtagene autoleucel in patients with heavily pretreated multiple myeloma, it was stated that the study added a new cohort of patients with prior exposure to therapies that, like orva-cel, target the BCMA antigen.
One study investigator pointed to the data for ADP-A2M4 as indicating much greater efficacy in the rare cancer than existing therapy options, while another said it demonstrated cell therapies' potential outside of the blood cancer space.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
Experts expressed dismay at single-agent data from the Phase I study, which a spokesperson noted was still in dose expansion. However, the drug could have a future in combinations or in patients with minimal disease left over after prior treatment.
The company is seeking approval for Yescarta in follicular and marginal zone lymphomas. While it has a clear efficacy advantage over existing therapy options, experts said whether to use it in their place will entail complicated conversations with patients.
Phase I/II data for pralsetinib in non-small cell lung cancer are the subject of a poster presented at the ASCO meeting. An expert noted the similarity between its clinical activity and that of Lilly's drug, Retevmo. Both are RET inhibitors.
The company presented Phase Ib data for magrolimab, a CD47 inhibitor, in AML and MDS. An interviewed executive and an investigator expressed particular excitement about complete responses in a poor-prognosis patient subset, in addition to the general AML population.
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.
While cautioning that it's still early days, experts said the data - especially those showing much lower toxicity - raise the prospect that the therapy could replace autologous CAR-Ts, if its efficacy remains the same.
Under the 10-year deal, Gilead will have the right to option product candidates from Arcus' pipeline, with the companies sharing responsibility for development and commercialization.
The company said the DREAMM-2 study of belantamab mafodotin, its antibody-drug conjugate that targets BCMA, showed a median overall survival of nealry 15 months in heavily pretreated patients.
The company will present data from the Phase I trial of teclistamab in an oral session at the ASCO virtual meeting later this month. The drug, a bispecific monoclonal antibody against the antigen BCMA, is a potential competitor to a similar therapy developed by Amgen.
Data on the CAR-T, JNJ-4528, will be presented at the ASCO virtual meeting. In an interview, a J&J executive talked about how the therapy could be developed for outpatient use through patient self-monitoring.